abstract |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)). |